US HIV Drugs Market Analysis Report 2022 to 2030

US HIV Drugs Market Analysis

$ 3999

US HIV Drugs Market is at around $13.31 Bn in 2023 and is projected to reach $14.88 Bn in 2030, exhibiting a CAGR of 1.6% during the forecast period. The market is driven by rising HIV prevalence, improvements in drug development, and increased testing and awareness campaigns. The market is dominated by key players like Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffman-La Roche Ltd., Cipla, Teva Pharmaceutical Industries Ltd., and Johnson & Johnson.

ID: IN10USPH011 CATEGORY: Pharmaceuticals GEOGRAPHY: US AUTHOR: Aneri Parekh

Buy Now

US HIV Drugs Market Executive Summary

US HIV Drugs Market is at around $13.31 Bn in 2023 and is projected to reach $14.88 Bn in 2030, exhibiting a CAGR of 1.6% during the forecast period.

The US market for HIV drugs caters to the creation, production, and dispensing of pharmaceuticals intended for the control and treatment of HIV/ AIDS in the US. This market includes a variety of antiretroviral medications and treatments designed to slow HIV's spread, increase patient quality of life, and suppress the infection.

Innovative therapies and greater accessibility to medication are driving the US market for HIV drugs. The primary emphasis of major businesses is the development of combination medicines and long-acting formulations to enhance patient outcomes. Developments in antiretroviral therapy, enhanced diagnosis, and growing awareness all contribute to the market's growth. Other elements that impact the market include the increase in HIV drug clinical trials, the presence of advanced medical facilities, and the high healthcare spending from local government agencies.

The global HIV medications market has grown significantly, estimated at $31.7 Bn in 2023. Rising diagnosis rates and government attempts to raise knowledge about HIV management have positively impacted the HIV drug industry. The market landscape is shifting with increased generic competition. The path forward relies on eliminating affordability limitations, addressing stigma, and ensuring greater access to treatment in underdeveloped nations.

Gilead has the greatest market share in the US HIV drug industry, with over 60%. This dominance stems mostly from their blockbuster medicine Biktarvy, a single-tablet regimen for HIV therapy. Gilead significantly spends in R&D, constantly adding new HIV medications and innovations to its pipeline to ensure its long-term market presence.

US HIV drugs market

Market Dynamics

Market Growth Drivers:

Rising HIV Prevalence: Antiretroviral therapy (ART) medicine demand is driven by the rising prevalence of HIV-positive people.

Drug Development Advancements: New and more potent HIV medications are introduced as a result of ongoing research and development. These developments frequently lead to the creation of novel pharmacological classes, formulations, and combination treatments, all of which increase market share.

Increasing Awareness and Testing Initiatives: Early diagnosis and treatment initiation are facilitated by greater access to HIV testing and intensified awareness campaigns, which propels the market for HIV drugs.

Market Restraints:

Pricing and Affordability: Patients who lack sufficient insurance coverage or financial resources may find the high cost of HIV medications to be a major obstacle. This may make it more difficult for people to get treatment and follow their drug plans.

Patent Expiration and Generic Competition: When major HIV treatments' patents expire, generic substitutes may become available, which could lower the market share and financial success of branded drugs. Pharmaceutical businesses may face pricing pressure as a result of this.

Discrimination and Stigma: Despite advancements in HIV prevention and treatment, stigma and discrimination against those living with HIV/ AIDS continue. This may discourage people from obtaining care, testing, and treatment, which could lower the demand for HIV medications on the market.

Notable Recent Updates

September 2023, the US Food and Drug Administration (USFDA) has tentatively approved Viatris Inc., a multinational healthcare corporation, for a new drug application. With this approval, a drug specifically intended to treat HIV-1 infection in pediatric patients, abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension, can now be prescribed

Healthcare Policies and Regulatory Landscape

The regulatory body in charge of overseeing pharmaceuticals in the US is the Food and Drug Administration (FDA). The FDA ensures that new drugs are safe and effective by evaluating and approving them. Pre-clinical, clinical, and FDA review are the three primary phases of the development process for most new therapeutic drugs and biologics. The process of obtaining a license for a pharmaceutical involves several difficulties, including stringent rules, costly and time-consuming development schedules, and difficulties with clinical trials.

Competitive Landscape

Key Players:

Gilead Sciences
ViiV Healthcare
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Merck & Co.
Bristol-Myers Squibb
AbbVie Inc.
F. Hoffman-La Roche Ltd.
Cipla
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Drugs Market Segmentation

By Drug Class

Integrase Inhibitors
Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combination HIV Medicines
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.